The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Cross Country Healthcare to Knox Lane for $13.25 per share in cash. The firm originally launched its investigation because Cross Country Healthcare had previously agreed in December 2024 to be acquired by Aya Healthcare for $18.61 per share in cash, a deal that was terminated in December 2025 due to regulatory delays. The proposed sale to Knox Lane, announced on May 6, 2026, is nearly 29% lower than the Aya offer. Wohl & Fruchter also noted that in March 2026, a Benchmark analyst raised the target price to $14.00 per share and a Wedbush analyst raised it to $15.00 per share, both citing improving outlook and profitability recovery. The renewed investigation follows the firm's review of the definitive proxy filed on June 15, 2026, ahead of a shareholder vote scheduled for July 16, 2026.
Cross Country Healthcare IncProposed sale to Knox Lane at $13.25/share is 29% lower than the prior Aya offer of $18.61/share, and law firm investigation raises fairness concerns.